DarkHorse Podcast Pharma’s New Game: The 279th Evolutionary Lens with Bret Weinstein and Heather Heying
49 snips
Jun 4, 2025 The hosts dive into the controversial FDA approval of Moderna's new mRNA vaccine, raising concerns about transparency and efficacy. They tackle the complexities of public discourse and the challenges of discerning truth amidst competing narratives. A captivating discussion on the gender identity controversy surrounding an Algerian boxer highlights the nuances of biological observation versus interpretation. Finally, they explore the role of religion in societal cohesion and reflect on the intersection of pathogens and cultural evolution.
AI Snips
Chapters
Books
Transcript
Episode notes
Moderna's New Vaccine Dose Lowers Risk?
- The new Moderna mRNA COVID-19 vaccine significantly reduces the active dose compared to the original shot.
- Lower dosage might reduce harm but unclear if efficacy is maintained due to insufficient information.
Pharma's Trial Control Risk
- Pharma often controls its own trials through contractors with vested interests.
- This structure allows for gaming trial results without clear blindness or accountability.
Lack of Mucosal Immunity Is Intentional
- COVID shots fail to induce mucosal immunity, the key barrier to respiratory virus infection.
- Pharma benefits by letting disease spread to maintain market demand for vaccines.
